Clinical Trial Update: Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG [Phase 3]

View source ↗

Summary

Phase 3 trial update for Vicinium in non-muscle invasive bladder cancer previously treated with BCG has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Vicinium (etileucel? (Note: Vicinium is an investigational antibody-drug conjugate; if uncertain, use Vicinium as brand and leave generic_null))

Snippet

Sponsor: Sesen Bio, Inc. | Conditions: Bladder Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-07-24